Usefulness and safety of oral cryotherapy in the prevention of oral mucositis after conditioning regimens with high-dose melphalan for autologous stem cell transplantation for lymphoma and myeloma

Eur J Haematol. 2014 Dec;93(6):487-91. doi: 10.1111/ejh.12386. Epub 2014 Jun 21.

Abstract

Background: Oral mucositis (OM) is a common complication of conditioning regimens with high-dose melphalan (HDmel). This retrospective cohort study analyzes the impact of oral cryotherapy (OC) or room temperature saline rinses on the prevention of OM in patients with multiple myeloma (MM) or lymphoid neoplasias submitted to autologous stem cell transplantation (ASCT) in a single center.

Patients and methods: From August 2006 to July 2011, 134 consecutive patients were enrolled. Two consecutive groups were included: Non-OC (August 2006 to April 2009, 68 patients) and OC (May 2009 to July 2011, 66 cases). MM cases (78, 58%) received HDmel as the conditioning regimen and 56 patients (42%) with lymphoma received BEAM.

Results: The non-OC and OC groups were comparable for the main clinicobiologic features and type of neoplasia. OM was more frequent and severe in patients receiving BEAM as the conditioning therapy. The group of OC showed less frequent and less severe mucositis and fewer days on antibiotics. No differences were observed in the duration of OM, need for parenteral nutrition and narcotics, and the length of hospital stay on comparison with the OC and non-OC groups. By multivariate analyses, OC was an independent favorable prognostic factor for OM development.

Conclusions: This study shows that OC is more effective than saline rinses in the prevention of OM in patients with lymphoma and myeloma receiving conditioning regimens with HDmel for ASCT.

Keywords: high-dose melphalan; oral cryotherapy; oral mucositis.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Female
  • Hematopoietic Stem Cell Transplantation
  • Humans
  • Hypothermia, Induced* / adverse effects
  • Hypothermia, Induced* / methods
  • Incidence
  • Lymphoma / complications*
  • Lymphoma / therapy
  • Male
  • Melphalan / administration & dosage*
  • Middle Aged
  • Multiple Myeloma / complications*
  • Multiple Myeloma / therapy
  • Myeloablative Agonists / administration & dosage*
  • Prognosis
  • Retrospective Studies
  • Stomatitis / diagnosis
  • Stomatitis / epidemiology
  • Stomatitis / etiology*
  • Stomatitis / prevention & control*
  • Transplantation Conditioning / adverse effects*
  • Transplantation, Autologous
  • Treatment Outcome
  • Young Adult

Substances

  • Myeloablative Agonists
  • Melphalan